Direct Meds GLP-1 vs Elevate Health

Recorded prices, access and terms.

Decision table

The entries below are recorded provider statements unless a regulatory source is linked. A provider webpage does not independently verify its licenses or quality. Direct Meds GLP-1 source · Elevate Health source.

CompareDirect Meds GLP-1Elevate Health
Recorded medication/program subtotalRecorded medication and program subtotal — semaglutide: $249/month; tirzepatide: $297/month. Other required fees, labs, dose changes and renewal terms: unconfirmed. This is not a verified all-in treatment cost.Monthly-plan rate unconfirmed. Advertised headline prices may require prepayment, a specific dose or introductory terms. Full required cost is unconfirmed.
Full required monthly costUnconfirmed: consultation, labs, membership, dose changes and shipping must be checkedUnconfirmed: consultation, labs, membership, dose changes and shipping must be checked
Drug type listedCompoundedCompounded
ConsultationIncluded in the record; current conditions unconfirmedFree in the record; current conditions unconfirmed
Pharmacy licenseNot independently verified. Obtain the dispensing pharmacy name and verify its state license.Not independently verified. Obtain the dispensing pharmacy name and verify its state license.
Reported states45; confirm eligibility and clinician licensing in your state50; confirm eligibility and clinician licensing in your state
CancellationCancellation reported; notice, minimum term and refund conditions unconfirmedCancellation reported; notice, minimum term and refund conditions unconfirmed
Clinician/support as reportedLicensed providersLicensed providers, unlimited telehealth visits, blood work included
Recorded provider check2026-09-13No date recorded

Which should you choose?

Ask each provider for the full cost at your prescribed dose, required labs and visits, the dispensing pharmacy, the clinician's state license, renewal charges and written refund terms. Compare those answers with your clinician.

Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness or quality before marketing. FDA source and recommendations.

Direct Meds GLP-1: evidence and terms

Recorded FDA letter (2025-09-09): FDA found claims on directmeds.com that its compounded semaglutide and tirzepatide contain 'the same active ingredient' as the brand drugs false or misleading, making the products misbranded under FD&C Act sections 502(a) and 502(bb). FDA letter.

Read Direct Meds GLP-1's sourced record · Direct Meds GLP-1 source

Visit Direct Meds GLP-1

Elevate Health: evidence and terms

Read Elevate Health's sourced record · Elevate Health source

Compare the full provider directory · Compare recorded price subtotals

Compare providersVisit Embody →